Molecularly targeted cancer therapies, such as small-molecule kinase inhibitors and
monoclonal antibodies, constitute a rapidly growing and an important part of the oncology …

Central nervous system (CNS) involvement from breast cancer (BC) has been historically
considered a relatively rare event. However, the development of new therapeutic strategies …

We critically examined long-term cardiovascular (CV) outcomes and overall survival (OS) of
breast cancer (BC) patients who had cardiotoxicity during adjuvant trastuzumab treatment …

Purpose The aim of this study was to determine risk factors for brain metastasis as the first
site of disease recurrence in patients with HER2-positive early-stage breast cancer (EBC) …

Aim We aimed to assess the survival benefit of epidermal growth factor receptor 2 (HER2)-
positive breast cancer patients with brain metastasis (BM) after whole-brain radiotherapy …

In a previous study of breast cancer patients, we found changes in cardiac function and size
during the early stages of adjuvant trastuzumab (Herceptin®) therapy. Here we present a …

Trastuzumab has been demonstrated to be an effective treatment in patients with human
epidermal growth factor receptor‑2 (HER‑2) positive breast cancer (BC); however …

В обзоре обсуждаются механизмы кардио-токсического действия трастузумаба;
представлены факторы риска развития дисфункции левого желудочка при лечении …

The incidence of metastatic disease in the central nervous system (CNS) is rising. According
to current estimates, up to a third of adult cancer patients will suffer from CNS metastasis …